Jeil Pharma Holdings Inc
KRX:002620
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7 020
9 280
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| KR |
|
Jeil Pharma Holdings Inc
KRX:002620
|
123.1B KRW |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
954.4B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
268.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.9B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
219B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
265.9B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
147.8B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
94.4B EUR |
Loading...
|
Market Distribution
| Min | -163 055.6% |
| 30th Percentile | -2.2% |
| Median | 2.7% |
| 70th Percentile | 6.8% |
| Max | 22 874.8% |
Other Profitability Ratios
Jeil Pharma Holdings Inc
Glance View
Jeil Pharma Holdings, Inc. engages in the management of its subsidiaries. The company is headquartered in Seoul, Seoul. The firm provides antibiotics, anti-inflammatory painkillers, hepatitis remedies, duodenum ulcer treatments, anticancer drugs, tristimania drugs, gastritis drugs, stomach ulcer drugs, septicemia treatments, pollakisuria treatments, acute bronchitis remedies, hyperlipidemia treatments and others. The firm distributes its products within domestic market and to overseas markets.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Jeil Pharma Holdings Inc is 5.1%, which is above its 3-year median of -3.6%.
Over the last 3 years, Jeil Pharma Holdings Inc’s Operating Margin has increased from -3.8% to 5.1%. During this period, it reached a low of -8% on Mar 31, 2023 and a high of 5.1% on Sep 30, 2025.